Anti-malarial drug resistance is a serious international health problem and a major obstacle for malaria control efforts in Africa. In 2002, a collaborative project was established to expand an existing surveillance system for the monitoring of anti-malarial drug resistance at seven sentinel sites in Uganda with a focus on combination anti-malarial therapy. The overall goal of my project is to utilize data collected from these surveillance sites, molecular tools, and cutting-edge analytical techniques to best characterize anti-malarial drug resistance in Uganda and further our understanding of the determinants of drug resistance.
The specific aims of the project are as follows: 1) To optimize the results of a large national drug surveillance study by evaluating the impact of extended follow-up and genotyping on estimates of the efficacies of combination regimens for the treatment of uncomplicated malaria in Uganda. 2) To evaluate molecular markers of sulfadoxine-pyrimethamine and chloroquine resistance as predictors of clinical treatment outcomes. 3) To identify individual and community level risk factors for anti-malarial drug resistance. Data will come from ongoing randomized clinical trials comparing sulfadoxine/pyrimethamine (SP) + chloroquine (CQ) to SP + amodiquine (AQ) for the treatment of uncomplicated falciparum malaria at each of the seven sentinel sites. An AQ + artesunate (AS) treatment arm will be included at three of the sites. Of note, SP+CQ is the new national first-line therapy for uncomplicated malaria, SP+AQ was superior in our prior studies, and AQ+AS is a promising new regimen of great international interest. Estimates of treatment efficacy using the standard 14-day WHO protocol will be compared with those using a 28-day follow-up protocol including molecular genotyping to distinguish recrudescence from new infections. Parasite DNA will be used to determine whether polymorphisms in key parasite genes (dhfr, dhps, pfcrt) predict clinical response to therapy. Multivariate analysis will be used to identify population and individual risk factors for markers of anti-malarial drug resistance and clinical treatment failure. The results of these investigations will provide key information for the formulation of rational malaria treatment policies and contribute to our understanding of the mechanisms of anti-malarial drug resistance.

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01TW000007-06
Application #
6929080
Study Section
Special Emphasis Panel (ZRG1-ICP-3 (01))
Program Officer
Jessup, Christine
Project Start
1999-09-30
Project End
2006-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
6
Fiscal Year
2005
Total Cost
$102,600
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Roxby, Alison C; Ben-Youssef, Leïla; Marx, Grace et al. (2016) Dual contraceptive method use in HIV-serodiscordant Kenyan couples. J Fam Plann Reprod Health Care 42:264-270
Tusting, Lucy S; Bousema, Teun; Smith, David L et al. (2014) Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol 84:151-208
Gantt, Soren; Huang, Meei-Li; Magaret, Amalia et al. (2013) An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol 58:276-8
Mabuka, Jennifer; Goo, Leslie; Omenda, Maxwel M et al. (2013) HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. AIDS 27:1535-44
Nsobya, Samuel L; Dokomajilar, Christian; Joloba, Moses et al. (2007) Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother 51:3023-5
Dokomajilar, Christian; Nsobya, Samuel L; Greenhouse, Bryan et al. (2006) Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 50:1893-5
Francis, Damon; Nsobya, Samuel L; Talisuna, Ambrose et al. (2006) Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193:978-86